Undergoing antiviral therapy can reduce the risk of liver cancer among patients who have chronic hepatitis B infection, two new studies that have been published in the journal Gastroenterology reveal. In the first paper,1/a researchers from National Yang-Ming University in Taiwan showed that the licensed oral antiviral agent nucleos(t)ide (NUC) resulted in a reduced long-term risk for liver cancer in a large, nationwide cohort of chronic hepatitis B patients. ...
Read More
No comments:
Post a Comment